Synthetic cajanin stilbene acid derivatives inhibit c-MYC in breast cancer cells

Archives of Toxicology

Volumn 90, Issue 3, 2016, Pages 575-588

  Kadioglu, Onat ^a   Fu, Yujie ^b   Wiench, Benjamin ^a   Zu, Yuangang ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Breast cancer; c MYC; Cajanin stilbene acid; Microarray; Pharmacogenomics

Indexed keywords

3-HYDROXY-4-PRENYL-5-METHOXYSTILBENE-2-CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; CAJANINE; DIETHYLSTILBESTROL; SALICYLIC ACID DERIVATIVE; STILBENE DERIVATIVE;

ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMISTRY; DNA MICROARRAY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF-7 CELL LINE; MOLECULAR DOCKING; ONCOGENE MYC; PATHOLOGY; PROCEDURES; PROMOTER REGION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIETHYLSTILBESTROL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MCF-7 CELLS; MOLECULAR DOCKING SIMULATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; SALICYLATES; STILBENES;

EID: 84958158649     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1480-2     Document Type: Article

References (50)

1. Adams JM, Harris AW, Pinkert CA et al (1985) The c-MYC oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318(6046):533–538
2. Addou-Klouche L, Adelaide J, Cornen S et al (2012) Integrated genomic analysis of breast cancers. Balkan J Med Genet BJMG 15(Suppl):71–74. doi:10.2478/v10034-012-0023-x
3. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101–112. doi:10.1038/nrc721
4. Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB (1995) Synergistic interaction of transforming growth factor alpha and c-MYC in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ Mol Biol J Am Assoc Cancer Res 6(6):737–748
5. Arnold I, Watt FM (2001) c-MYC activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol CB 11(8):558–568
6. Bhardwaj A, Rosen D, Liu M et al (2014) suppression of Akt-mTOR pathway—a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS ONE 9(5):e97076. doi:10.1371/journal.pone.0097076
7. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H (1990) Sequence-specific DNA binding by the c-MYC protein. Science 250(4984):1149–1151
8. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-MYC, cyclin D1 and cyclin E. Endocr Relat Cancer 12(Suppl 1):S47–S59. doi:10.1677/erc.1.00993
9. Byler S, Goldgar S, Heerboth S et al (2014) Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 34(3):1071–1077
10. Cartharius K, Frech K, Grote K et al (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21(13):2933–2942. doi:10.1093/bioinformatics/bti473
11. Castro F, Dirks WG, Fahnrich S, Hotz-Wagenblatt A, Pawlita M, Schmitt M (2013) High-throughput SNP-based authentication of human cell lines. Int J Cancer 132(2):308–314. doi:10.1002/ijc.27675
12. Chen Y, Olopade OI (2008) MYC in breast tumor progression. Expert Rev Anticancer Ther 8(10):1689–1698. doi:10.1586/14737140.8.10.1689
13. Cheng AS, Jin VX, Fan M et al (2006) Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 21(3):393–404. doi:10.1016/j.molcel.2005.12.016
14. Clarke R, Liu MC, Bouker KB et al (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47):7316–7339. doi:10.1038/sj.onc.1206937
15. Clausen DM, Guo J, Parise RA et al (2010) In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-MYC/MAX dimerization. J Pharmaco Exp Ther 335(3):715–727. doi:10.1124/jpet.110.170555
16. D’Cruz CM, Gunther EJ, Boxer RB et al (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7(2):235–239. doi:10.1038/84691
17. Eichhorn T (2011) Molecular biology, pharmacogenomics and bioinformatics of natural compounds and synthetic compounds for cancer therapy. Ph.D. Thesis. Ruperto-Carola University of Heidelberg, Germany
18. Escot C, Theillet C, Lidereau R et al (1986) Genetic alteration of the c-MYC protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83(13):4834–4838
19. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4(2):199–207
20. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ (2008) Structural rationale for the coupled binding and unfolding of the c-MYC oncoprotein by small molecules. Chem Biol 15(11):1149–1155. doi:10.1016/j.chembiol.2008.09.011
21. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G (1988) Overexpression of either c-MYC or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncog Res 3(1):21–31
22. Harrington EA, Bennett MR, Fanidi A, Evan GI (1994) c-MYC-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13(14):3286–3295
23. Jonkers J, Berns A (2004) Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6(6):535–538. doi:10.1016/j.ccr.2004.12.002
24. Kallio MA, Tuimala JT, Hupponen T et al (2011) Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genom 12:507. doi:10.1186/1471-2164-12-507
25. Kim J, Lee JH, Iyer VR (2008) Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS ONE 3(3):e1798. doi:10.1371/journal.pone.0001798
26. Kim B, Fatayer H, Hanby AM et al (2013) Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS ONE 8(5):e62766. doi:10.1371/journal.pone.0062766
27. Kirkland JL, Murthy L, Stancel GM (1992) Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology 130(6):3223–3230. doi:10.1210/endo.130.6.1375896
28. Musgrove EA, Sergio CM, Loi S et al (2008) Identification of functional networks of estrogen- and c-MYC-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE 3(8):e2987. doi:10.1371/journal.pone.0002987
29. Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193–205
30. Nicholson RI, Hutcheson IR, Britton D et al (2005) Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93(2–5):257–262. doi:10.1016/j.jsbmb.2004.12.006
31. Parris TZ, Kovacs A, Hajizadeh S et al (2014) Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11–p12-amplified breast carcinomas. Oncogenesis 3:e95. doi:10.1038/oncsis.2014.8
32. Pavesi G, Pesole G (2006) Using Weeder for the discovery of conserved transcription factor binding sites. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis et al. Chapter 2: Unit 2 11. doi:10.1002/0471250953.bi0211s15
33. Pelengaris S, Khan M, Evan G (2002a) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2(10):764–776. doi:10.1038/nrc904
34. Pelengaris S, Khan M, Evan GI (2002b) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109(3):321–334
35. Plourde KV, Labrie Y, Desjardins S et al (2013) Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families. J Hum Genet 58(2):59–66. doi:10.1038/jhg.2012.127
36. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ (2005) Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 41(16):2485–2501. doi:10.1016/j.ejca.2005.08.017
37. Prendergast GC, Ziff EB (1992) A new bind for Myc. Trends Genet TIG 8(3):91–96
38. Schuldiner O, Benvenisty N (2001) A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 20(36):4984–4994. doi:10.1038/sj.onc.1204459
39. Shachaf CM, Kopelman AM, Arvanitis C et al (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431(7012):1112–1117. doi:10.1038/nature03043
40. Shang Y, Baumrucker CR, Green MH (1998) c-MYC is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells. J Biol Chem 273(46):30608–30613
41. Sousa SF, Fernandes PA, Ramos MJ (2006) Protein-ligand docking: current status and future challenges. Proteins 65(1):15–26. doi:10.1002/prot.21082
42. Venditti M, Iwasiow B, Orr FW, Shiu RP (2002) c-MYC gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 99(1):35–42
43. Vennstrom B, Sheiness D, Zabielski J, Bishop JM (1982) Isolation and characterization of c-MYC, a cellular homolog of the oncogene (v-MYC) of avian myelocytomatosis virus strain 29. J Virol 42(3):773–779
44. Wang YH, Liu S, Zhang G et al (2005) Knockdown of c-MYC expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res BCR 7(2):R220–R228. doi:10.1186/bcr975
45. Wang H, Hammoudeh DI, Follis AV et al (2007) Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 6(9):2399–2408. doi:10.1158/1535-7163.MCT-07-0005
46. Wu N, Kong Y, Fu Y et al (2011) In vitro antioxidant properties, DNA damage protective activity, and xanthine oxidase inhibitory effect of cajaninstilbene acid, a stilbene compound derived from pigeon pea [Cajanus cajan (L.) Millsp.] leaves. J Agric Food Chem 59(1):437–443. doi:10.1021/jf103970b
47. Yan Y, Zhang GX, Williams MS et al (2012) TCR stimulation upregulates MS4a4B expression through induction of AP-1 transcription factor during T cell activation. Mol Immunol 52(2):71–78. doi:10.1016/j.molimm.2012.04.011
48. Yap JL, Wang H, Hu A et al (2013) Pharmacophore identification of c-MYC inhibitor 10074-G5. Bioorg Med Chem Lett 23(1):370–374. doi:10.1016/j.bmcl.2012.10.013
49. Ziv-Av A, Taller D, Attia M et al (2011) RTVP-1 expression is regulated by SRF downstream of protein kinase C and contributes to the effect of SRF on glioma cell migration. Cell Signal 23(12):1936–1943. doi:10.1016/j.cellsig.2011.07.001
50. Zu YG, Liu XL, Fu YJ, Wu N, Kong Y, Wink M (2010) Chemical composition of the SFE-CO extracts from Cajanus cajan (L.) Huth and their antimicrobial activity in vitro and in vivo. Phytomedicine Int J Phytotherapy Phytopharm 17(14):1095–1101. doi:10.1016/j.phymed.2010.04.005